Advertisement

Pharmacy World and Science

, Volume 17, Issue 6, pp 178–185 | Cite as

Prospects of immunotherapy for rheumatoid arthritis

  • Bert A. 't Hart
  • Henny G. Otten
Reviews

Abstract

The main challenge in the development of new modalities for the treatment of rheumatoid arthritis is to enhance the specificity while reducing the adverse side-effects of therapeutics. Biotechnology provides a variety of reagents, such as monoclonal antibodies, recombinant cytokines, cytokine antagonists, and small peptides, with the potential to interfere with selected stages of the disease process in a highly specific manner. In addition, several new therapeutic approaches have emerged as a result of extensive research with animal models of disease, including T-cell vaccination and bone marrow transplantation. This article discusses current insights into the pathogenesis of rheumatic diseases, focusing on rheumatoid arthritis. A number of new therapeutic modalities for rheumatoid arthritis, in particular those acting on the immune system, are discussed. Because it is not possible to provide a complete overview of all the developments in the field in limited space, a selection of strategies and modalities which are representative of the broad variety of immunotherapeutic approaches currently used are highlighted.

Keywords

Antibodies, monoclonal Arthritis, rheumatoid Bone marrow transplantation Cytokines Immunotherapy Pathology Peptides Prognosis Vaccination 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rasker JJ, Cosh JA. Course and prognosis of early rheumatoid arthritis. Scand J Immunol 1989;79:45–56.Google Scholar
  2. 2.
    Wilke WS, Sweeney TJ, Calabrese LH. Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome. Semin Arthritis Rheum 1993;23:26–41.PubMedGoogle Scholar
  3. 3.
    Nepom GT, Byers P, Seyfried C, Healey LA, Wilske KR, Stage D, et al. HLA genes associated with rheumatoid arthritis. Arthritis Rheum 1989;32:15–21.PubMedGoogle Scholar
  4. 4.
    Carson D, Chen P, Kipps TJ. New roles for rheumatoid factor. J Clin Invest 1991;87:379–38.PubMedGoogle Scholar
  5. 5.
    Tarkowski A, Klareskog L, Carlsten H, Herberts P, Koopman W. Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum 1989;32:1087–90.PubMedGoogle Scholar
  6. 6.
    Londei M, Savill CM, Verhoef A, Brennan F, Leech ZA, Duance V. Persistence of collagen type II-specific T cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci USA 1989;86:636–64.PubMedGoogle Scholar
  7. 7.
    De Graeff-Meeder ER, Voorhorst-Ogink MM, van Eden W, Schuurman HJ, Huber J, Barkley D, et al. Antibodies to the mycobacterial 65 kD heat-shock protein are reactive with synovial tissue of adjuvant arthritic rats and patients with rheumatoid arthritis and osteoarthritis. Am J Pathol 1990; 137:1013–7.PubMedGoogle Scholar
  8. 8.
    Van Boxel JA, Paget SA. Predominantly T cell infiltrate in rheumatoid synovial membranes. N Engl J Med 1975;293: 51–20Google Scholar
  9. 9.
    Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990;33:768–73.PubMedGoogle Scholar
  10. 10.
    Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:72–7.Google Scholar
  11. 11.
    Schwartz BD. Infectious agents immunity and rheumatic diseases. Arthritis Rheum 1990;33:457–65.PubMedGoogle Scholar
  12. 12.
    Van Eden W, Thole JER, van der Zee R, Noordzij A, van Embden JDA, Hensen EJ, et al. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 1988;331:171–3.PubMedGoogle Scholar
  13. 13.
    Holoshitz J, Koning F, Coligan JE, Bruyn J, Strober J. Isolation of CD4-CD8-mycobacteria-reactive T lymphocyte clones from rheumatoid arthritis synovial fluid. Nature 1989;339: 226–9.PubMedGoogle Scholar
  14. 14.
    Van Eden W, Holoshitz J, Nevo Z, Frenkel A, Klajman A, Cohen IR. Arthritis induced by a T lymphocyte clone that responds toMycobacterium tuberculosis and to cartilage proteoglycan. Proc Natl Acad Sci USA 1985;82:5117–20.PubMedGoogle Scholar
  15. 15.
    Wilkin TJ. The primary lesion theory of autoimmunity: a speculative hypothesis. Autoimmunity 1990;7:225–35.PubMedGoogle Scholar
  16. 16.
    Cremer MA, Townes AS, Kang AH. Adjuvant-arthritis in rats. Evidence that autoimmunity to homologous collagens types I, II, IX, XI is not involved in the pathogenesis of arthritis. Clin Exp Immunol 1990;82:307–12.PubMedGoogle Scholar
  17. 17.
    Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155–7.PubMedGoogle Scholar
  18. 18.
    Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365–75.PubMedGoogle Scholar
  19. 19.
    Chin JR, Murphy G, Werb Z. Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. J Biol Chem 1985;260:12367–76.PubMedGoogle Scholar
  20. 20.
    Nguyen Q, Murphy G, Roughley PJ, Mort JS. Degradation of proteoglycan aggregate by a cartilage metalloproteinase: evidence for the involvement of stromelysin in the generation of link protein heterogeneityin situ. Biochem J 1989; 259:61–7.PubMedGoogle Scholar
  21. 21.
    Geppert TD, Jasin HE. Antigen presentation in the joint. J Rheumatol 1991;18:309–11.PubMedGoogle Scholar
  22. 22.
    Miller LC, Dinarello CA. Biological activities of interleukin-1 relevant to rheumatic diseases. Pathol Immunopathol Res 1987;6:22–36.PubMedGoogle Scholar
  23. 23.
    Miossec P, Dinarello CA, Ziff M. Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid. Arthritis Rheum 1986;29:461–70.PubMedGoogle Scholar
  24. 24.
    Ming WJ, Bersani L, Montevani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol 1987;138:1469–74.PubMedGoogle Scholar
  25. 25.
    Various authors. Adhesion molecules. Immunol Rev 1990; 114:1–217.Google Scholar
  26. 26.
    Duke O, Panayi GS, Janossy G, Poulter LW. An immunohistological study of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol 1982;49:22–30.PubMedGoogle Scholar
  27. 27.
    Rème T, Portier M, Frayssinoux F, Combe B, Miossec P, Favier F, et al. T cell receptor expression and activation of synovial lymphocytes in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:485–92.PubMedGoogle Scholar
  28. 28.
    Holoshitz J. Potential role of γδ T cells in autoimmune diseases. Res Immunol 1990;141:651–7.PubMedGoogle Scholar
  29. 29.
    Gaston JSH, Life PF, Jenner PJ, Colston MJ, Bacon PA. Recognition of a mycobacteria-specific epitope in the 65 kD heat shock protein by synovial fluid-derived T cell clones. J Exp Med 1990;171:831–41.PubMedGoogle Scholar
  30. 30.
    Van Eden W. Heat-shock proteins in autoimmune arthritis: A critical contribution based on the adjuvant arthritis model. Apmis 1990;98:383–94.PubMedGoogle Scholar
  31. 31.
    Van den Broek M. Streptococcal cell wall-induced polyarthritis in the rat. Mechanisms for chronicity and regulation of susceptibility. APMIS 1989;97:861–78.PubMedGoogle Scholar
  32. 32.
    Hazenberg MP, Klasen IS, Kool J, Ruseler-van Embden JGH, Severeijnen AJ. Are intestinal bacteria involved in the etiology of rheumatoid arthritis. APMIS 1992;100:1–9.PubMedGoogle Scholar
  33. 33.
    Horneff G, Burmester GR, Emmrich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991;34:129–40.PubMedGoogle Scholar
  34. 34.
    Quayle A, Kjeldsen-Kragh J, Føre O, Waalen K, Sioud M, Kalvenes C, et al. Immunoregulatory T cell subsets and T cell activation in rheumatoid arthritis. Springer Semin Immunopathol 1989;11:273–87.PubMedGoogle Scholar
  35. 35.
    Persson DA, Sharp JT, Lidsky MD. The cytotoxicity of leukocytes and lymphocytes from patients with rheumatoid arthritis for synovial cells. J Clin Invest 1976;58:690–8.PubMedGoogle Scholar
  36. 36.
    Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H. Evidence in support of a self-perpetuating HLA-DR-dependent delayed type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 1982;79:3632–6.PubMedGoogle Scholar
  37. 37.
    Sakane T, Takada S, Murakawa Y, Kotani H, Honda M, Ueda Y. Analysis of suppressor T cell function in patients with rheumatoid arthritis: defects in production of and responsiveness to concanavalin A-induced suppressor T cells. J Immunol 1982;129:1972–7.PubMedGoogle Scholar
  38. 38.
    Bakker NPM, van Erck MG, Zurcher C, Faaber P, Lemmens A, Hazenberg M, et al. Experimental immune-mediated arthritis in rhesus monkeys: a model for rheumatoid arthritis? Rheumatol Int 1990;10:21–9.PubMedGoogle Scholar
  39. 39.
    Holmdahl R, Andersson M, Goldschmidt TJ, Gustaffson K, Jansson L, Mo JA. Type II collagen autoimmunity and provocations leading to arthritis. Immunol Rev 1990;118:193–32.PubMedGoogle Scholar
  40. 40.
    Van den Broek MF, van den Berg WB, Arntz OJ, van de Putte LBA. Reaction of bacterium-primed murine T cells to cartilage components: a clue to the pathogenesis of arthritis? Clin Exp Immunol 1988;72:9–14.PubMedGoogle Scholar
  41. 41.
    Van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a follow-up study. J Rheumatol 1993;20: 1288–96PubMedGoogle Scholar
  42. 42.
    Van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992;51:1029–35.PubMedGoogle Scholar
  43. 43.
    Harris ED. Rheumatoid arthritis: the clinical spectrum. In: Kelley, WN, Harris ED, Ruddy S, Sledge CB, editors. Text-book of rheumatology. 2nd ed.Add city: WB Saunders, 1985:915–50.Google Scholar
  44. 44.
    Van der Heide DM, van 't Hoff M, van Riel PL, van de Putte LB. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 1993; 20:538–41.PubMedGoogle Scholar
  45. 45.
    Fife RS. Imaging, arthroscopy and markers in osteoarthritis. Curr Opin Rheumatol 1992;4:560–5.PubMedGoogle Scholar
  46. 46.
    Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of non-steroidal anti-inflammatory drugs with upper gastro-intestinal tract bleeding. Arch Int Med 1987;147:85–8.Google Scholar
  47. 47.
    Mackenzie AH. Antimalarial drugs for rheumatoid arthritis. Am J Med 1983;75:48–58.Google Scholar
  48. 48.
    Howard-Lock HE, Lock CJL, Mewa A, Kean WF. D-Penicillamine: chemistry and clinical use in rheumatic diseases. Semin Arthritis Rheum 1986;15:261–81.PubMedGoogle Scholar
  49. 49.
    Boerbooms AMT, Jeurissen MEC, Westgeest AAA, Theunisse H, van de Putte LBA. Methotrexate in refractory rheumatoid arthritis. Clin Rheumatol 1988;7:249–53.PubMedGoogle Scholar
  50. 50.
    Grindulis KA, McConkey B. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine or dapsone. Ann Rheum Dis 1984;43:398–401.PubMedGoogle Scholar
  51. 51.
    Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for 11 years. BMJ 1985;243: 420–3.Google Scholar
  52. 52.
    Davis P. Undesirable effects of gold salts. J Rheumatol 1979;6 Suppl:18–24.Google Scholar
  53. 53.
    Van Rijthoven AWAM, Dijkmans BC, Goei Thé HS, Herman J, Montnor-Beckers ZLBM, Jacobs PJC, et al. Cyclosporin treatment for rheumatoid arthritis: a placebo-controlled double-blind multicenter study. Ann Rheum Dis 1986;45:726–31.PubMedGoogle Scholar
  54. 54.
    Wilder RL. Treatment of the patient with rheumatoid arthritis refractory to standard therapy. JAMA 1988;259:2446–9.PubMedGoogle Scholar
  55. 55.
    Tsokos GC. Immunomodulatory treatment in patients with rheumatic diseases: mechanisms of action. Semin Arthritis Rheum 1987;17:24–9.PubMedGoogle Scholar
  56. 56.
    Bach JF, Fracchia GN, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. Immunol Today 1993;14:421–5.PubMedGoogle Scholar
  57. 57.
    Beverley PCL, Riethmuller G. Immunological intervention with monoclonal antibodies. Immunol Today 1987;8:101–2.Google Scholar
  58. 58.
    Horneff G, Winkler T, Kalden J, Emmrich F, Burmester GR. Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis. Clin Immunol Immunopathol 1991;59:89–103.PubMedGoogle Scholar
  59. 59.
    Jonker M, Den Brok JH. Idiotypic switching of CD4-specific monoclonal antibodies can prolong the therapeutic effectiveness in spite of host anti-mouse IgG antibodies. Eur J Immunol 1987;17:1547–53.PubMedGoogle Scholar
  60. 60.
    Morrison SL, Johnson MJ, Herzenberg LA, Oi V. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851–5.PubMedGoogle Scholar
  61. 61.
    Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433–55.PubMedGoogle Scholar
  62. 62.
    Jonker M, Slingerland W, Treacy G, van Eerd P, Pak KY, Wilson E, et al.In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees. Clin Exp Immunol 1993; 93:301–7.PubMedGoogle Scholar
  63. 63.
    Verwilghen J, Kingsley GH, Ceuppens JL, Panayi GS. Inhibition of synovial fluid T cell proliferation by anti-CD5 monoclonal antibodies. A potential mechanism for their immunotherapeutic actionin vivo. Arthritis Rheum 1992; 35:1445–51.PubMedGoogle Scholar
  64. 64.
    Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1993;36:620–30.PubMedGoogle Scholar
  65. 65.
    Choy EH, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992;36:291–8.PubMedGoogle Scholar
  66. 66.
    Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. Arthritis Rheum 1994;37: 834–8.PubMedGoogle Scholar
  67. 67.
    Van der Lubbe PA, Reiter C, Miltenburg AM, Kruger K, de Ruyter AN, Rieber EP, et al. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action. Scand J Immunol 1994;39:286–94.PubMedGoogle Scholar
  68. 68.
    Van der Lubbe PA, Reiter C, Breedveld FC, Kruger K, Schattenkirchner M, Sanders ME, et al. Chimeric CD4 monoclonal antibody CM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993;36:1375–9.PubMedGoogle Scholar
  69. 69.
    Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993;36:307–18.PubMedGoogle Scholar
  70. 70.
    Horneff G, Emmrich F, Burmester GR. Advances in immunotherapy of rheumatoid arthritis: clinical and immunological findings following treatment with anti-CD4 antibodies. Br J Rheumatol 1993;32 Suppl 4:39–47.Google Scholar
  71. 71.
    Wendling D, Racadot E, Morel-Fourrier B, Wijdenes J. Treatment of rheumatoid arthritis with anti CD4 monoclonal antibody. Open study of 25 patients with the B-F5 clone. Clin Rheumatol 1992;11:542–7.PubMedGoogle Scholar
  72. 72.
    Racadot E, Wijdenes J, Wendling D. Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5) [see comments. Clin Exp Rheumatol 1992;10:365–74.PubMedGoogle Scholar
  73. 73.
    Wendling D, Wijdenes J, Racadot E, Morel-Fourrier B. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 1991;18:325–7.PubMedGoogle Scholar
  74. 74.
    Goldberg D, Morel P, Chatenoud L, Boitard C, Menkes CJ, Bertoye PH, et al. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun 1991;4:617–30.PubMedGoogle Scholar
  75. 75.
    Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmuller G, Kruger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991;34:525–36.PubMedGoogle Scholar
  76. 76.
    Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC. Lack of clinical effect of CD4 monoclonal antibody therapy in early rheumatoid arthritis. A placebo controlled trial [abstract]. Arthritis Rheum 1994;37 Suppl:Abstr 807.Google Scholar
  77. 77.
    Tak PP, van der Lubbe PA, Daha MR, Smeets TJM, Kluin PM, Meinders E, et al. Reduction of synovial inflammation after anti-CD4 antibody treatment in early rheumatoid arthritis [abstract]. Arthritis Rheum 1994;37 Suppl:Abstr 1056.Google Scholar
  78. 78.
    Twistlethaite JR, Stuart JK, Mayes JT, Gabler AO, Woodle S, Buckingham MR, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988;11:112–9.PubMedGoogle Scholar
  79. 79.
    Kirkham BW, Thien F, Pelton BK, Pitzalis C, Amlot P, Denman AM, et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992;19:1348–52.PubMedGoogle Scholar
  80. 80.
    Kirkham BW, Pitzalis C, Kingsley GH, Chikanza IC, Sabharwal S, Barbatis C, et al. Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1991;30:459–63.PubMedGoogle Scholar
  81. 81.
    Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748–52.PubMedGoogle Scholar
  82. 82.
    Kyle V, Roddy J, Hale G, Hazleman BL, Waldmann H. Humanized monoclonal antibody treatment in rheumatoid arthritis. J Rheumatol 1991;18:1737–8.PubMedGoogle Scholar
  83. 83.
    Watts RA, Isaacs JD, Hale G, Hazleman BL, Waldmann H. Peripheral blood lymphocyte subsets after CAMPATH-1H therapy for RA — a 3 year follow-up [abstract]. Arthritis Rheum 1994;37 Suppl:Abstr 1061.Google Scholar
  84. 84.
    Weinblatt ME, Coblyn J, Maier A, Anderson R, Helfgott S, Thurmond L, et al. Continued lymphocyte suppression following single dose Mab therapy with CAMPATH-1H;A 20 month follow-up [abstract]. Arthritis Rheum 1994; 37(Suppl):Abstr 1548.Google Scholar
  85. 85.
    Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM. Synovial tissue response to treatment with CAMPATH-1H. Arthritis Rheum 1995;38:254–8.PubMedGoogle Scholar
  86. 86.
    Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992–9.PubMedGoogle Scholar
  87. 87.
    Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis. Arthritis Rheum 1995;38:151–60.PubMedGoogle Scholar
  88. 88.
    Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33:305–15.PubMedGoogle Scholar
  89. 89.
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681–90PubMedGoogle Scholar
  90. 90.
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105–10.PubMedGoogle Scholar
  91. 91.
    Dreylow B, Capezio J, Lovis R, Jacobs C, Landay A, Pope RM. Phase I study of recombinant human interleukin-1 and tumor necrosis factor α in rheumatoid arthritis [abstract]. Arthritis Rheum 1993;36 Suppl:Abstr 39.Google Scholar
  92. 92.
    Lebsack ME, Paul CC, Bloedow DC, Burch FX, Sack MA, Catalano MA. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1991;34 Suppl:Abstr 45.Google Scholar
  93. 93.
    Kingsley G, Panayi GS. Management of early inflammatory arthritis. Intervention with immunomodulatory agents: T cell vaccination. Bailliere's Clin Rheumatol 1992;6:435–54.Google Scholar
  94. 94.
    Van Laar JM, Miltenburg AM, Verdonk MJ, Leow A, Elferink BG, Daha MR, et al. Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis. J Autoimmunol 1993;6:159–67.Google Scholar
  95. 95.
    Lohse A, Cohen IR. Mechanisms of resistance to autoimmune disease induced by T cell vaccination. Autoimmunity 1991;9:119–21.PubMedGoogle Scholar
  96. 96.
    Thompson HSG, Staines NA. Gastric administration of type II collagen delays the onset and severity of collageninduced arthritis. Clin Exp Immunol 1986;64:581–6.PubMedGoogle Scholar
  97. 97.
    Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993;261:1727–30.PubMedGoogle Scholar
  98. 98.
    Van Bekkum DW, Bohré EPM, Houben PFJ, Knaan-Shanzer S. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci USA 1989;86:10090–4.PubMedGoogle Scholar
  99. 99.
    Ishida T, Inaba M, Hisha H, Sugiura K, Adachi Y, Nagata N, et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogenic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol 1994;152:3119–27PubMedGoogle Scholar
  100. 100.
    Van Bekkum DW. BMT in experimental autoimmune diseases. Bone Marrow Transplant 1993;11:183–7.PubMedGoogle Scholar
  101. 101.
    Lowenthal RM, Cohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 1993;20:137–40.PubMedGoogle Scholar
  102. 102.
    Baldwin JL, Storb R, Thomas ED, Mannik M. Bone marrow transplantation in patients with gold-induced marrow aplasia. Arthritis Rheum 1977;20:1043–8.PubMedGoogle Scholar
  103. 103.
    Jacobs P, Vincent MD, Martell RW. Prolonged remission of severe refractory rheumatoid arthritis following allogenic bone marrow transplantation for drug-induced aplastic anemia. Bone Marrow Transplant 1986;1:237–9PubMedGoogle Scholar
  104. 104.
    Mant MJ, Russell AS, Percy JS, Davis P, Messner HA. Immunosuppression as initial treatment for gold induced aplastic anemia. J Rheumatol 1987;14:1026–9.PubMedGoogle Scholar
  105. 105.
    Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993;328:593–602.PubMedGoogle Scholar
  106. 106.
    Cavagnaro J. Immunotoxicology and the new biotechnology. Immunol Today 1987;8:102–4.Google Scholar
  107. 107.
    Bach JF, Fracchia GN, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. Immunol Today 1993;14:421–5.PubMedGoogle Scholar
  108. 108.
    Müller-Eberhardt HJ. Complement. Annu Rev Biochem 1975;44:697–724.PubMedGoogle Scholar
  109. 109.
    Jonker M, Bakker K, Slierendregt B, t' Hart B, Bontrop R. Autoimmunity in nonhuman primates: the role of major histocompatibility complex and T cells and implications for therapy. Hum Immunol 1991;32:31–40.PubMedGoogle Scholar
  110. 110.
    Jonker M, Slingerland W. Reactivity of monoclonal antibodies specific for human CD markers with rhesus monkey leukocytes. In: Knapp W, Dørken B, Rieber EP, Stein H, Gilks WR, Schmidt RE, et al., editors. Leukocyte typing IV, white cell differentiation antigens. Oxford: Oxford University Press, 1989:1058–63.Google Scholar
  111. 111.
    Jonker M, Slingerland W, van der Meide P, 't Hart B. Reactivity of human cytokine receptor-specific monoclonal antibodies with rhesus monkey leukocytes. In: Schlossmann SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, et al., editors. Leukocyte typing V. White cell differentiation antigens. Vol 2. Oxford: Oxford University Press, 1995: 1973–5.Google Scholar
  112. 112.
    't Hart B, Slingerland W, Jonker M. Reactivity of antihuman leukocyte integrin-specific monoclonal antibodies with rhesus monkey blood leukocytes. In: Schlossmann SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, et al., editors. Leukocyte typing V. White cell differentiation antigens. Vol 2. Oxford: Oxford University Press, 1995: 1605–6.Google Scholar

Copyright information

© Royal Dutch Association for the Advancement of Pharmacy 1995

Authors and Affiliations

  • Bert A. 't Hart
    • 1
  • Henny G. Otten
    • 2
  1. 1.Department of ImmunobiologyBiomedical Primate Research CentreGH RijswijkThe Netherlands
  2. 2.Department of Immuno-HaematologyUniversity HospitalUtrechtThe Netherlands

Personalised recommendations